<DOC>
<DOCNO>
EP-0015339
</DOCNO>
<TEXT>
<DATE>
19800917
</DATE>
<IPC-CLASSIFICATIONS>
C07D-235/00 C07D-235/30 
</IPC-CLASSIFICATIONS>
<TITLE>
separation of syn and anti 1-alkylsulfonyl-2-amino-5(6)hydroximinomethylbenzimidazole derivatives.
</TITLE>
<APPLICANT>
lilly co elius<sep>eli lilly and company<sep>eli lilly and company307, east mccarty streetindianapolis indiana 46285us<sep>
</APPLICANT>
<INVENTOR>
shyan-ell su kennethus<sep>templeton robert joseph us <sep>wikel james howardus<sep>shyan-ell su, kenneth<sep>templeton, robert joseph<sep>wikel, james howard<sep>shyan-ell su, kenneth8530 trials run roadindianapolis, indiana 46217us<sep>templeton, robert joseph525, south restin roadgreenwood, indiana 46142us<sep>wikel, james howard4068 sunshine waygreenwood, indiana 46142us<sep>
</INVENTOR>
<ABSTRACT>
to separate the syn and anti oximes of the formula    wherein r¹ is c₁-c₅ alkyl; and r² is phenyl, or phenyl sub­ stituted by c₁-c₄ alkyl, c₁-c₄ alkoxy, chloro, bromo, iodo,  nitro or trifluoromethyl, e. g.  1-isopropylsulfonyl-2-amino-­ 6-(α-hydroximinobenzyl)-benzimidazole, a mixture of these  oximes is dissolved in a water miscible organic solvent  selected from methyl ethyl ketone, methanol, ethanol,  isopropanol, acetonitrile, dimethylacetamide, dimethyl  sulfoxide and, preferably, acetone, a sufficient quantity of  water is added to initiate crystallization, and the precipi­ tated anti oxime isomer which displays good antiviral acti­ vity is separated, e. g.  in greater than about 95% purity.  
</ABSTRACT>
</TEXT>
</DOC>
